


PHARMACEUTICAL 2022

Aurinia Pharmaceuticals Inc. Rank 126 of 466







PHARMACEUTICAL 2022



Aurinia Pharmaceuticals Inc. Rank 126 of 466

The relative strengths and weaknesses of Aurinia Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aurinia Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Aurinia Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 212%, being 134% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	513,324
Cost of Goods Sold	1,091
Intangible Assets	8,404
Liabilities, Current	40,646
Liabilities, Non-Current	23,630
Other Assets	17,221
Other Compr. Net Income	-47
Other Expenses	3,432
Other Liabilities	0
Other Net Income	529
Other Revenues	45,605
Property and Equipment	4,418
Research and Development	51,139
Selling, General and Administrative Expense	171,438

Output Variable	Value in 1000 USD
Assets	543,367
Liabilities	64,276
Expenses	227,100
Revenues	45,605
Stockholders Equity	479,091
Net Income	-180,966
Comprehensive Net Income	-180,990
Economic Capital Ratio	212%

